Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LncRNA Neighboring Enhancer of FOXA2 (LNCNEF) is a long non-coding RNA molecule involved in the modulation of gene expression by enhancer-like mechanisms, particularly influencing FOXA2 and pathways such as TGF-β signaling. It acts as a tumor suppressor in certain cancers, notably hepatocellular carcinoma and small cell lung cancer, where its downregulation is associated with metastasis and poor prognosis. In ankylosing spondylitis, LNCNEF is upregulated and correlated with disease activity and recurrence, making it a novel candidate biomarker for disease monitoring. LNCNEF represents a potential target for therapeutic modulation, though direct targeting in drugs has not been achieved, and further research is needed to clarify its molecular functions and clinical utility.
For nonsteroidal anti-inflammatory drugs: indirect downregulation of LNCNEF by reducing inflammation. For potential future drugs: hypothetical interference with lncRNA expression or function, not yet established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LncRNA Neighboring Enhancer of FOXA2 (LNCNEF).